Novartis building

Novartis’ Entresto Nabs FDA Approval for New Heart Failure Indication

February 19, 2021

The FDA has approved an expanded indication for Novartis’ heart failure combination therapy Entresto (sacubitril/valsartan).

The new approval allows the combination therapy to be used to reduce the risk of cardiovascular death and hospitalization in adults with chronic heart failure.

Specifically, the expanded indication notes that the benefits are most evident for patients whose left ventricular ejection fraction is below normal.

View today's stories